Europe
Under the terms of the agreement, Celsius will use its single-cell genomics and machine learning platform to attempt to identify predictive biomarkers from Janssen’s VEGA Phase IIa clinical trial.
ADC Therapeutics, headquartered in Lausanne, Switzerland, closed on a $103 million Series E financing expansion, bringing the total proceeds to $303 million.
There is, thankfully, no age limit on innovation—you can do it at any age. But for many, “young,” counts as under 30, sometimes under 35, or even under 40, at least in terms of putting together lists of scientific innovators.
The introduction of EHLs allowed hemophilia patients to live a life beyond their disease, with improved quality of life, the study showed.
This makes it one of the biggest single private funding rounds for a biotechnology company in European history.
Vivoryon Therapeutics AG and MorphoSys AG today announced that they have entered into an agreement under the terms of which MorphoSys has obtained an exclusive option to license Vivoryon’s small molecule QPCTL inhibitors in the field of oncology.
sterna biologicals GmbH & Co. KG (sterna) announced that the Company has recently appointed Dr. Marion Wencker as consulting Chief Medical Officer and Dr. Thomas Klaue as consulting Chief Financial Officer.
Simbec-Orion, Europe’s leading full-service boutique CRO, announces its new unified brand offering comprising the divisions previously known as Simbec Research, Orion Clinical, Orion Santé and Seirian Laboratories.
Evotec SE announced the formation of Breakpoint Therapeutics GmbH, a spin-off company focusing on the development of Evotec’s DNA damage response (“DDR”) portfolio, comprising discovery-stage assets and drug targets that promise broad therapeutic application in a variety of cancers.
The three-drug combination of encorafenib, binimetinib and cetuximab significantly improved overall survival in patients with BRAF-mutated metastatic colorectal cancer, according to results of the BEACON CRC Phase III clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.
PRESS RELEASES